Culmerciclib for HR+ HER2+ advanced breast cancer
Part of Cancer, Skin clinical trials.
This study tests a new drug called Culmerciclib for women with a certain type of advanced breast cancer that has both hormone receptors and HER2. It’s for patients whose cancer has been stable on at least 4 cycles of prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman 18 or older with advanced breast cancer that cannot be removed by surgery or has spread to other parts of the body.
- Your breast cancer must test positive for both hormone receptors (ER or PR) and the HER2 protein.
- You must have tumor tissue available for extra testing (like looking at your genes).
- You have already received at least 4 cycles of chemotherapy or other treatment for your advanced cancer, and your cancer did not get worse on that treatment.
- You are well enough to do daily activities (ECOG score 0 or 1) and expected to live at least 12 more weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Culmerciclib for women with advanced HR-positive, HER2-negative breast cancer that has stopped responding to a CDK4/6 inhibitor with hormone therapy. The goal is to see if giving this drug again can help when other treatments no longer work.
This trial tests a combination of three drugs (culmerciclib, letrozole, and two HER2-targeting drugs) given before surgery to shrink breast cancers that are hormone-receptor positive and HER2 positive.
This trial tests a new medicine called fulvestaciclib combined with hormone therapy and anti-HER2 treatment for advanced breast cancer that is hormone receptor-positive and HER2-positive. It is for patients who have not had prior treatment for advanced disease and may help control tumor growth.
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
This trial tests a combination of a new immunotherapy drug (adebrelimab) with a targeted pill (dalpiciclib) and standard hormone therapy for women with advanced hormone receptor positive, HER2 negative breast cancer. It may help patients who have not yet had certain prior treatments, aiming to slow the cancer's growth.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.